Ngm biopharmaceuticals inc (NGM)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18
Related party revenue

102,356

103,544

119,580

118,827

115,604

108,665

0

0

0

Operating expenses:
Research and development

138,165

129,253

116,240

111,760

105,787

95,714

0

0

0

General and administrative

24,859

23,631

22,330

21,529

18,758

17,265

0

0

0

Total operating expenses

163,024

152,884

138,570

133,289

124,545

112,979

0

0

0

Loss from operations

-60,668

-49,340

-18,990

-14,462

-8,941

-4,314

0

0

0

Interest income

6,757

6,692

6,151

5,133

3,980

3,622

0

0

0

Other income (expense), net

269

-147

150

40

141

199

0

0

0

Net loss

-53,642

-42,795

-12,689

-9,289

-4,820

-493

0

0

0

Net loss per share, basic and diluted

-0.28

0.66

-0.17

-0.13

-1.21

2.23

-1.15

-0.52

-0.64

Weighted average shares used to compute net loss per share, basic and diluted

67,396

67,385

65,948

61,044

6,812

6,682

6,525

6,200

6,127